Is GlobeImmune, Inc. (GBIM) a Buy, Sell, or Hold?
OTC : GBIM
GlobeImmune, Inc.
$0.0001 USD
$0.0 (9900.0%)
- Volume
- 800
- Average Volume
- 532
- Market Capitalization
- $575
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.62
Company Overview
OTC
Donald Bellgrau
Biotechnology
Healthcare
GBIM
2
US
USD
Liquidity Metrics
0.00
2.62
2.62
2.34
0.00
Sales & Valuation
$6.46M
0.00
0.00
0.00
-1.25
Profitability
-$0.48
-$2.77M
-42.85%
-42.85%
-64.41%
-24.05%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-31.84
2/9
$5.3M
$9.77M
$7.62M
-$2.07M
Key Metrics (TTM)
-$9.9M
-1.53
3.84
2.62
-64.41%
-38.00%
-481069.18%
-1246163.30%
-32 days
Company Executives
| Name | Title |
|---|---|
| Donald Bellgrau | Scientific Founder & Chairman of The Scientific Advisory Board |
Poll Results
No votes yet today — be the first to share your view!
About GlobeImmune, Inc. (OTC:GBIM) Stock
GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases. Central to its development efforts is its unique Tarmogen platform. The company's pipeline includes several key candidates: For infectious diseases: GS-4774 is currently in Phase 2 clinical trials, designed to treat individuals chronically infected with the hepatitis B virus who are also on oral antiviral suppressive therapy. Additionally, GlobeImmune has various other infectious disease programs in the preclinical stage, such as GI-19000 for tuberculosis, GI-2010 for human immunodeficiency virus (HIV), and GI-18000 for hepatitis D virus ... infections. For oncology: GlobeImmune is advancing GI-6301, which targets cancers characterized by the expression of the brachyury protein. GI-6207 is progressing through Phase 2 clinical trials for medullary thyroid cancer. Furthermore, GI-4000 is a significant asset, undergoing Phase 2b clinical trials for resected pancreatic cancer, and is also in separate Phase 2 trials for non-small cell lung cancer and colorectal cancer. To support its endeavors, GlobeImmune maintains strategic alliances with industry leaders such as Gilead Sciences, Inc. and Celgene Corporation.
Frequently Asked Questions
-
What is the current GlobeImmune, Inc. (GBIM) stock price?
-
GlobeImmune, Inc.(OTC:GBIM) stock price is $0.0001 in the last trading session. During the trading session, GBIM stock reached the peak price of $0.0001 while $0.000001 was the lowest point it dropped to. The percentage change in GBIM stock occurred in the recent session was 9900.0% while the dollar amount for the price change in GBIM stock was $0.0.
-
GBIM's industry and sector of operation?
-
The OTC listed GBIM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GBIM?
-
Donald Bellgrau | Scientific Founder & Chairman of The Scientific Advisory Board
|
|
|
| -
How many employees does GBIM have?
-
Number of GBIM employees currently stands at 2. GBIM operates from 1450 Infinite Drive, Louisville, CO 80027, US.
-
Link for GBIM official website?
-
Official Website of GBIM is: https://www.globeimmune.com
-
How do I contact GBIM?
-
GBIM could be contacted at phone #303 625 2700 and can also be accessed through its website. GBIM operates from 1450 Infinite Drive, Louisville, CO 80027, US.
-
How many shares of GBIM are traded daily?
-
The average number of GBIM shares traded daily for last 3 months was 532.
-
What is the market cap of GBIM currently?
-
The market value of GBIM currently stands at $575 with its latest stock price at $0.0001